Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""sorafenib"" wg kryterium: Temat


Tytuł :
Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye.
Autorzy :
Santonocito M; Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio-Aci S. Antonio, 95025 Catania, Italy.
Zappulla C; Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio-Aci S. Antonio, 95025 Catania, Italy.
Viola S; Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio-Aci S. Antonio, 95025 Catania, Italy.
La Rosa LR; Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio-Aci S. Antonio, 95025 Catania, Italy.
Solfato E; Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio-Aci S. Antonio, 95025 Catania, Italy.
Abbate I; Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio-Aci S. Antonio, 95025 Catania, Italy.
Tarallo V; Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso'-CNR, 80131 Napoli, Italy.
Apicella I; Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso'-CNR, 80131 Napoli, Italy.
Platania CBM; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.
Maugeri G; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.
D'Agata V; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.
Bucolo C; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.
De Falco S; Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso'-CNR, 80131 Napoli, Italy.
Mazzone MG; Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio-Aci S. Antonio, 95025 Catania, Italy.
Giuliano F; Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio-Aci S. Antonio, 95025 Catania, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Apr 22; Vol. 22 (9). Date of Electronic Publication: 2021 Apr 22.
Typ publikacji :
Journal Article
MeSH Terms :
Choroidal Neovascularization/*drug therapy
Diabetes Mellitus, Experimental/*complications
Diabetic Retinopathy/*drug therapy
Nanostructures/*administration & dosage
Retinal Diseases/*drug therapy
Retinal Neovascularization/*drug therapy
Sorafenib/*pharmacology
Administration, Ophthalmic ; Animals ; Diabetic Retinopathy/etiology ; Diabetic Retinopathy/pathology ; Disease Models, Animal ; Emulsions ; Female ; Male ; Mice ; Mice, Inbred C57BL ; Nanostructures/chemistry ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacology ; Rabbits ; Rats ; Rats, Sprague-Dawley ; Retinal Diseases/pathology ; Sorafenib/administration & dosage
Czasopismo naukowe
Tytuł :
Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression.
Autorzy :
Jaffar Ali D; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China; Key Laboratory for Developmental Genes and Human Disease, Ministry of Education, Institute of Life Sciences, Jiangsu Province High-Tech Key Laboratory for Bio-Medical Research, Southeast University, Nanjing, Jiangsu 210096, China.
He C; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China.
Xu H; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China.
Kumaravel S; Department of Medical Physiology, College of Medicine, Texas A & M Health Science Center, College Station, TX 77843, United States of America.
Sun B; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China.
Zhou Y; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Liu R; Department of Genetic Engineering, College of Natural Science, University of Suwon, Kyunggi-Do 445-743, Republic of Korea.
Xiao Z; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Apr 15; Vol. 271, pp. 119149. Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Journal Article
MeSH Terms :
Cell-Derived Microparticles/*metabolism
Drug Resistance, Neoplasm/*physiology
Forkhead Box Protein M1/*biosynthesis
Liver Neoplasms/*metabolism
Sorafenib/*pharmacology
Tumor Suppressor Protein p53/*metabolism
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Dose-Response Relationship, Drug ; Drug Resistance, Neoplasm/drug effects ; Female ; Gene Expression Regulation, Neoplastic ; Hep G2 Cells ; Humans ; Liver Neoplasms/drug therapy ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Sorafenib/therapeutic use ; Tumor Suppressor Protein p53/antagonists & inhibitors ; Xenograft Model Antitumor Assays/methods
Czasopismo naukowe
Tytuł :
MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.
Autorzy :
Cheng Z; Department of General Surgery, The First Affiliated Hospital of Soochow University, Soochow, China.
Ni Q; Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, China.
Qin L; Department of General Surgery, The First Affiliated Hospital of Soochow University, Soochow, China.
Shi Y; Department of General Surgery, The First Affiliated Hospital of Soochow University, Soochow, China.
Pokaż więcej
Źródło :
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas [Braz J Med Biol Res] 2021 May 31; Vol. 54 (9), pp. e10390. Date of Electronic Publication: 2021 May 31 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Drug Resistance, Neoplasm*
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
MicroRNAs*/genetics
Sorafenib*/pharmacology
Cell Line, Tumor ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Humans ; PTEN Phosphohydrolase/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction ; TOR Serine-Threonine Kinases
Czasopismo naukowe
Tytuł :
Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Autorzy :
Liu X; Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology of Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Zhu X; Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology of Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Qi X; Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology of Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Meng X; Laboratory of Controllable Preparation and Application of Nanomaterials, Laboratory of Cryogenics, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, People's Republic of China.
Xu K; Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology of Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2021 Feb 11; Vol. 16, pp. 1037-1050. Date of Electronic Publication: 2021 Feb 11 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Ferroptosis*/drug effects
Iron/*chemistry
Liver Neoplasms/*drug therapy
Metal-Organic Frameworks/*chemistry
Oligopeptides/*administration & dosage
Oligopeptides/*therapeutic use
Sorafenib/*administration & dosage
Sorafenib/*therapeutic use
Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/pathology ; Endocytosis/drug effects ; Hep G2 Cells ; Humans ; Lipid Peroxidation/drug effects ; Liver Neoplasms/pathology ; Metal-Organic Frameworks/ultrastructure ; Mice ; Nanoparticles/chemistry ; Nanoparticles/toxicity ; Nanoparticles/ultrastructure ; Peroxidase/metabolism ; Rabbits ; Sorafenib/pharmacology ; Toxicity Tests
Czasopismo naukowe
Tytuł :
Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Autorzy :
Sbenati RM; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates.
Zaraei SO; Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul, 130-650, Republic of Korea; Department of Biomolecular Science, Korea University of Science and Technology, 113 Gwahangno, Yuseong-gu, Daejeon, 305-333, Republic of Korea.
El-Gamal MI; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates; Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates; Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, 35516, Egypt. Electronic address: .
Anbar HS; Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai, 19099, United Arab Emirates.
Tarazi H; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates; Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates.
Zoghbor MM; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates.
Mohamood NA; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates.
Khakpour MM; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates.
Zaher DM; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates.
Omar HA; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates; Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt.
Alach NN; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates.
Shehata MK; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates.
El-Gamal R; Department of Medical Biochemistry, Faculty of Medicine, University of Mansoura, Mansoura, 35516, Egypt.
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Jan 15; Vol. 210, pp. 113081. Date of Electronic Publication: 2020 Dec 04.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Antineoplastic Agents/*pharmacology
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Protein Kinases/*metabolism
Sorafenib/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Carcinoma, Hepatocellular/metabolism ; Carcinoma, Hepatocellular/pathology ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Liver Neoplasms/metabolism ; Liver Neoplasms/pathology ; Models, Molecular ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Sorafenib/chemical synthesis ; Sorafenib/chemistry ; Structure-Activity Relationship ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.
Autorzy :
Wen Z; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Feng Y; Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Hu Y; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Lian L; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Huang H; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Guo L; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Chen S; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yang Q; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Zhang M; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Wan L; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xu K; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Degejirifu; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yan X; Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, China.
Pokaż więcej
Źródło :
Aging [Aging (Albany NY)] 2021 Jan 13; Vol. 13 (2), pp. 1872-1882. Date of Electronic Publication: 2021 Jan 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Delivery Systems*
Nanotubes, Carbon*
Antineoplastic Agents/*therapeutic use
ErbB Receptors/*genetics
Liver Neoplasms/*drug therapy
RNA, Small Interfering/*therapeutic use
Sorafenib/*therapeutic use
Animals ; Antineoplastic Agents/administration & dosage ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; ErbB Receptors/metabolism ; Hep G2 Cells ; Humans ; Liver/drug effects ; Liver/metabolism ; Liver Neoplasms/genetics ; Mice ; Mice, Nude ; Neoplasm Transplantation ; RNA, Small Interfering/administration & dosage ; Sorafenib/administration & dosage
Czasopismo naukowe
Tytuł :
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Autorzy :
Su D; Department of Pharmacy, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
Wu B; Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shi L; Department of Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Pokaż więcej
Źródło :
JAMA network open [JAMA Netw Open] 2021 Feb 01; Vol. 4 (2), pp. e210037. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Sorafenib/*therapeutic use
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Agents/economics ; Antineoplastic Combined Chemotherapy Protocols/economics ; Bevacizumab/administration & dosage ; Carcinoma, Hepatocellular/pathology ; Cost-Benefit Analysis ; Decision Trees ; Disease Progression ; Drug Costs ; Female ; Humans ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Mortality ; Progression-Free Survival ; Proportional Hazards Models ; Quality-Adjusted Life Years ; Sorafenib/economics ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
Autorzy :
Hajiev S; Division of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Allara E; Division of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Motedayеn Aval L; Division of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Arizumi T; Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.
Bettinger D; Department of Medicine II, University Medical Center, Freiburg, Germany.; Berta-Ottenstein Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Pirisi M; Department of Translational Medicine, Università degli Studi del Piemonte Orientale, Novara, Italy.
Rimassa L; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano (Milan), Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy.
Pressiani T; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano (Milan), Italy.
Personeni N; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano (Milan), Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy.
Giordano L; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano (Milan), Italy.
Kudo M; Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.
Thimme R; Department of Medicine II, University Medical Center, Freiburg, Germany.
Park JW; National Cancer Centre Hospital, Goyang, South Korea.
Taddei TH; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Kaplan DE; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Ramaswami R; Division of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Pinato DJ; Division of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Sharma R; Division of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK. .
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2021 Jan; Vol. 124 (2), pp. 407-413. Date of Electronic Publication: 2020 Oct 19.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Sorafenib/*administration & dosage
Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Cohort Studies ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Sorafenib/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol.
Autorzy :
Karbownik A; Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861, Poznań, Poland. Electronic address: .
Miedziaszczyk M; Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861, Poznań, Poland.
Grabowski T; Polpharma Biologics SA, Trzy Lipy 3 Str., 80-172, Gdańsk, Poland.
Stanisławiak-Rudowicz J; Univeristy Hospital of Lord's Transfiguration, 84/86 Szamarzewskiego Str., 60-101, Poznań, Poland.
Jaźwiec R; Institute of Biochemistry and Biophysics PAS, Laboratory of Mas Spectromery, Polish Academy of Sciences, 5A Pawińskiego Str, 02-106, Warsaw, Poland.
Wolc A; Department of Animal Science, Iowa State University, 239E Kildee Hall, Ames, IA, 50011, USA; Hy-Line International, 2583 240th Street, Dallas Center, IA, 50063, USA.
Grześkowiak E; Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861, Poznań, Poland.
Szałek E; Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861, Poznań, Poland.
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2020 Oct; Vol. 130, pp. 110530. Date of Electronic Publication: 2020 Jul 23.
Typ publikacji :
Journal Article
MeSH Terms :
Adrenergic Uptake Inhibitors/*pharmacology
Antineoplastic Agents/*pharmacokinetics
Glucuronosyltransferase/*antagonists & inhibitors
Sorafenib/*pharmacokinetics
Tapentadol/*pharmacology
Animals ; Antineoplastic Agents/blood ; Area Under Curve ; Chromatography, High Pressure Liquid ; Drug Interactions ; Glucuronides/metabolism ; Male ; Rats ; Rats, Wistar ; Reproducibility of Results ; Sorafenib/blood ; Spectrophotometry, Ultraviolet ; Tandem Mass Spectrometry
Czasopismo naukowe
Tytuł :
Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real-life settings.
Autorzy :
Tak KY; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Seoul, South Korea.
Nam HC; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Seoul, South Korea.
Choi JY; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Seoul, South Korea.
Yoon SK; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Seoul, South Korea.
Kim CW; Uijeongbu St. Mary's Hospital, Seoul, South Korea.
Kim HY; Uijeongbu St. Mary's Hospital, Seoul, South Korea.
Lee SW; Bucheon St. Mary's Hospital, Seoul, South Korea.
Lee HL; Bucheon St. Mary's Hospital, Seoul, South Korea.
Chang UI; St. Vincent's Hospital, Seoul, South Korea.
Song DS; St. Vincent's Hospital, Seoul, South Korea.
Yang JM; Incheon St. Mary's Hospital, Seoul, South Korea.
Kwon JH; Incheon St. Mary's Hospital, Seoul, South Korea.
Yoo SH; Incheon St. Mary's Hospital, Seoul, South Korea.
Sung PS; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Seoul, South Korea.
Choi SW; St. Paul's Hospital, Seoul, South Korea.
Song MJ; Daejeon St. Mary's Hospital, Seoul, South Korea.
Kim SH; Daejeon St. Mary's Hospital, Seoul, South Korea.
Jang JW; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Seoul, South Korea.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2020 Oct 01; Vol. 147 (7), pp. 1970-1978. Date of Electronic Publication: 2020 Mar 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Sorafenib/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Dose-Response Relationship, Drug ; Drug Tapering ; Female ; Humans ; Male ; Medication Adherence ; Middle Aged ; Sorafenib/adverse effects ; Sorafenib/therapeutic use ; Survival Analysis ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma.
Autorzy :
Zhao T; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.; Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.
Wang C; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Huo X; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
He ML; Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.; CityU Shenzhen Research Institute, Shenzhen, China.
Chen J; Cancer Center, Taikang Xianlin Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, China.; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
Pokaż więcej
Źródło :
Journal of cellular and molecular medicine [J Cell Mol Med] 2020 Nov; Vol. 24 (21), pp. 12525-12536. Date of Electronic Publication: 2020 Oct 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Agents/*therapeutic use
Sorafenib/*therapeutic use
Stilbenes/*therapeutic use
Stomach Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Animals ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Autophagy/drug effects ; Cell Death/drug effects ; Cell Line, Tumor ; Cell Shape/drug effects ; Cell Survival/drug effects ; Drug Synergism ; G1 Phase Cell Cycle Checkpoints/drug effects ; Male ; Mice, Inbred BALB C ; Mice, Nude ; Sorafenib/pharmacology ; Stilbenes/chemistry ; Stilbenes/pharmacology ; Stomach Neoplasms/pathology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
[Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
Autorzy :
Chen X; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Jiang Y; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Zhang Y; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Dai W; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Fan R; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Weng X; Cancer Center, Hospital of Integrated Traditional and Western Medicine, Southern Medical University, Guangzhou 510310, China.
He P; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yan F; Cancer Center, Hospital of Integrated Traditional and Western Medicine, Southern Medical University, Guangzhou 510310, China.
Guo Y; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Pokaż więcej
Źródło :
Nan fang yi ke da xue xue bao = Journal of Southern Medical University [Nan Fang Yi Ke Da Xue Xue Bao] 2020 Oct 30; Vol. 40 (10), pp. 1488-1492.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Carcinoma, Hepatocellular*/drug therapy
Hand-Foot Syndrome*/drug therapy
Hand-Foot Syndrome*/etiology
Hand-Foot Syndrome*/prevention & control
Liver Neoplasms*/drug therapy
Ozone*/therapeutic use
Antineoplastic Agents/*adverse effects
Sorafenib/*adverse effects
Antineoplastic Agents/therapeutic use ; Humans ; Niacinamide/therapeutic use ; Phenylurea Compounds/adverse effects ; Quality of Life ; Sorafenib/therapeutic use
Czasopismo naukowe
Tytuł :
The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma.
Autorzy :
Zhang Z; Department of Liver Transplantation, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan Province, P.R. China.; Department of Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center Presbyterian Hospital, Pittsburgh, PA, 15213, USA.
Tan X; Department of Oncology, Xiangya Hospital, Central South University, 410008, Changsha, Hunan Province, P.R. China.
Luo J; Department of Liver Transplantation, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan Province, P.R. China.
Yao H; Department of General Surgery, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan Province, P.R. China.
Si Z; Department of Liver Transplantation, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan Province, P.R. China. .
Tong JS; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA. .
Pokaż więcej
Źródło :
Cell death & disease [Cell Death Dis] 2020 Oct 23; Vol. 11 (10), pp. 902. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Sorafenib*/metabolism
Sorafenib*/pharmacology
Carcinoma, Hepatocellular/*genetics
Drug Resistance, Neoplasm/*genetics
Liver Neoplasms/*genetics
MicroRNAs/*genetics
Animals ; Antineoplastic Agents/pharmacology ; Carcinoma, Hepatocellular/pathology ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Drug Resistance, Neoplasm/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Liver Neoplasms/pathology ; Mice ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery.
Autorzy :
Babos G; Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Magyar tudósok körútja 2, H-1117 Budapest, Hungary.; Research Institute of Biomolecular and Chemical Engineering, Faculty of Engineering, University of Pannonia, Egyetem u. 10, H-8200 Veszprém, Hungary.
Rydz J; Centre of Polymer and Carbon Materials Polish Academy of Sciences, 34, M. Curie-Skłodowskiej Str., 41-819 Zabrze, Poland.
Kawalec M; Centre of Polymer and Carbon Materials Polish Academy of Sciences, 34, M. Curie-Skłodowskiej Str., 41-819 Zabrze, Poland.
Klim M; Centre of Polymer and Carbon Materials Polish Academy of Sciences, 34, M. Curie-Skłodowskiej Str., 41-819 Zabrze, Poland.; Department of Microbiology and Virology School of Pharmacy with the Division of Laboratory Medicine Medical University of Silesia, 4 Jagiellońska St., 41-200 Sosnowiec, Poland.
Fodor-Kardos A; Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Magyar tudósok körútja 2, H-1117 Budapest, Hungary.; Research Institute of Biomolecular and Chemical Engineering, Faculty of Engineering, University of Pannonia, Egyetem u. 10, H-8200 Veszprém, Hungary.
Trif L; Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Magyar tudósok körútja 2, H-1117 Budapest, Hungary.
Feczkó T; Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Magyar tudósok körútja 2, H-1117 Budapest, Hungary.; Research Institute of Biomolecular and Chemical Engineering, Faculty of Engineering, University of Pannonia, Egyetem u. 10, H-8200 Veszprém, Hungary.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Oct 03; Vol. 21 (19). Date of Electronic Publication: 2020 Oct 03.
Typ publikacji :
Journal Article
MeSH Terms :
Colorectal Neoplasms/*drug therapy
Doxorubicin/*pharmacology
Nanoparticles/*chemistry
Sorafenib/*pharmacology
Colorectal Neoplasms/pathology ; Doxorubicin/chemistry ; Drug Carriers/chemistry ; Drug Carriers/pharmacology ; Drug Delivery Systems/methods ; HCT116 Cells ; Humans ; Polyethylene Glycols/chemistry ; Polyethylene Glycols/pharmacology ; Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; Polylactic Acid-Polyglycolic Acid Copolymer/pharmacology ; Sorafenib/chemistry
Czasopismo naukowe
Tytuł :
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Autorzy :
Lee JM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America. Electronic address: .
Annunziata CM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.
Hays JL; Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States of America.
Cao L; Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.
Choyke P; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.
Yu M; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.
An D; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.
Turkbey IB; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.
Minasian LM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.
Steinberg SM; Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, United States of America.
Chen H; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, United States of America.
Wright J; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, United States of America.
Kohn EC; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, United States of America.
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 Oct; Vol. 159 (1), pp. 88-94. Date of Electronic Publication: 2020 Aug 01.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Neoplasm Recurrence, Local/*drug therapy
Ovarian Neoplasms/*drug therapy
Sorafenib/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Humans ; Interleukin-8/blood ; Interleukin-8/immunology ; Middle Aged ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/mortality ; Ovarian Neoplasms/immunology ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Progression-Free Survival ; Response Evaluation Criteria in Solid Tumors ; Sorafenib/adverse effects
Czasopismo naukowe
Tytuł :
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Autorzy :
Sinn M; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Medical Oncology and Hematology, Berlin, Germany; Universitätsklinikum Hamburg-Eppendorf, Department of Medical Oncology, Hamburg, Germany. Electronic address: .
Liersch T; University of Göttingen, Department of General, Visceral and Pediatric Surgery, Göttingen, Germany.
Riess H; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Medical Oncology and Hematology, Berlin, Germany.
Gellert K; Sana Klinikum Lichtenberg, Department of General and Visceral Surgery, Berlin, Germany.
Stübs P; Otto-Guericke-University of Magdeburg, Department of General, Visceral and Vascular Surgery, Magdeburg, Germany.
Waldschmidt D; University of Köln, Department of Gastroenterology and Hepatology, Köln, Germany.
Lammert F; Universitätskliniken des Saarlandes, Department of Internal Medicine, Gastroenterology and Endocrinology, Homburg, Germany.
Maschmeyer G; Ernst von Bergmann Klinikum, Department of Hematology, Oncology and Palliative Care, Potsdam, Germany.
Bechstein W; Universitätsklinikum Frankfurt, Department of General and Visceral Surgery, Frankfurt, Germany.
Bitzer M; Eberhard-Karls-Universität Tübingen, Department of Internal Medicine, Tübingen, Germany.
Denzlinger C; Marienhospital Stuttgart, Department of Hematology, Oncology and Palliative Care, Stuttgart Germany.
Hofheinz R; Universitätsklinikum Mannheim, Department of Medical Oncology, Mannheim, Germany.
Lindig U; Universitätsklinikum Jena, Department of Hematology and Oncology, Jena, Germany.
Ghadimi M; University of Göttingen, Department of General, Visceral and Pediatric Surgery, Göttingen, Germany.
Hinke A; CCRC, Düsseldorf, Germany.
Striefler JK; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Medical Oncology and Hematology, Berlin, Germany.
Pelzer U; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Medical Oncology and Hematology, Berlin, Germany.
Bischoff S; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Medical Oncology and Hematology, Berlin, Germany.
Bahra M; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Surgery, Berlin, Germany.
Oettle H; Outpatient Department of Hematology/Oncology, Friedrichshafen, Germany.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Oct; Vol. 138, pp. 172-181. Date of Electronic Publication: 2020 Sep 02.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Pancreatectomy*/adverse effects
Pancreatectomy*/mortality
Adenocarcinoma/*therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Deoxycytidine/*analogs & derivatives
Pancreatic Neoplasms/*therapy
Sorafenib/*administration & dosage
Adenocarcinoma/mortality ; Adenocarcinoma/secondary ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Disease Progression ; Double-Blind Method ; Drug Administration Schedule ; Female ; Germany ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Sorafenib/adverse effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
Autorzy :
Damnernsawad A; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Department of Biology, Faculty of Science, Mahidol University, Bangkok.
Bottomly D; Division of Bioinformatics and Computational Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Kurtz SE; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Eide CA; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
McWeeney SK; Division of Bioinformatics and Computational Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Tyner JW; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR. .
Nechiporuk T; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR. .
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2020 Dec 30; Vol. Online ahead of print. Date of Electronic Publication: 2020 Dec 30.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Sorafenib*/pharmacology
Cell Line, Tumor ; Clustered Regularly Interspaced Short Palindromic Repeats ; Humans ; MAP Kinase Signaling System ; Mutation ; Niacinamide/pharmacology ; Niacinamide/therapeutic use ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; TOR Serine-Threonine Kinases/genetics ; Transcription Factors ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study.
Autorzy :
Lee S; Department of Radiology, Seoul National University Hospital, Jongno-gu, Seoul, Republic of Korea.
Kim JH; Department of Radiology, Seoul National University Hospital, Jongno-gu, Seoul, Republic of Korea.; Department of Radiology, Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea.; Institute of Radiation Medicine, Seoul National University Medical Research Center, Jongno-gu, Seoul, Republic of Korea.
Moon H; IMGT Co., Ltd., Bundang-gu, Seongnam, Republic of Korea.
Lee HJ; Department of Radiology, Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea.; IMGT Co., Ltd., Bundang-gu, Seongnam, Republic of Korea.; Department of Radiology, Seoul National University Bundang Hospital, Bundang-gu, Seongnam, Republic of Korea.
Han JK; Department of Radiology, Seoul National University Hospital, Jongno-gu, Seoul, Republic of Korea.; Department of Radiology, Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea.; Institute of Radiation Medicine, Seoul National University Medical Research Center, Jongno-gu, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Dec 11; Vol. 15 (12), pp. e0243815. Date of Electronic Publication: 2020 Dec 11 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Microbubbles*
Albumins/*chemistry
Carcinoma, Hepatocellular/*pathology
Doxorubicin/*pharmacology
Liver Neoplasms/*pathology
Nanoparticles/*chemistry
Sorafenib/*pharmacology
Animals ; Body Weight/drug effects ; Cell Line, Tumor ; Doxorubicin/chemistry ; Drug Carriers/chemistry ; Drug Interactions ; Feasibility Studies ; Humans ; Rats ; Sorafenib/chemistry ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications.
Autorzy :
Ebadi M; Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Selangor, Malaysia.
Bullo S; Department of Linguistic and Human Sciences, Begum Nusrat Bhutto Women University, Sukkur, Sindh, 65200, Pakistan.
Buskara K; Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.
Hussein MZ; Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Selangor, Malaysia. .
Fakurazi S; Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.; Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.
Pastorin G; Department of Pharmacy, National University of Singapore, Singapore, Singapore.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Dec 09; Vol. 10 (1), pp. 21521. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Delivery Systems/*methods
Sorafenib/*administration & dosage
3T3 Cells ; Animals ; Antineoplastic Agents/pharmacology ; Drug Liberation/physiology ; Hep G2 Cells ; Humans ; Liver/pathology ; Liver Neoplasms/drug therapy ; Magnetic Iron Oxide Nanoparticles/chemistry ; Magnetics ; Magnetite Nanoparticles/chemistry ; Mice ; Polyethylene Glycols/chemistry ; Polyvinyl Alcohol/chemistry ; Sorafenib/pharmacology ; Spectroscopy, Fourier Transform Infrared/methods ; X-Ray Diffraction/methods
Czasopismo naukowe
Tytuł :
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
Autorzy :
Saiyed M; Centre for Applied Health Economics, Griffith University, Nathan, QLD, 4111, Australia. .
Byrnes J; Centre for Applied Health Economics, Griffith University, Nathan, QLD, 4111, Australia.
Srivastava T; School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, S1 4DA, UK.
Scuffham P; Centre for Applied Health Economics, Griffith University, Nathan, QLD, 4111, Australia.; Menzies Health Institute Queensland, Griffith University, Nathan, QLD, 4111, Australia.
Downes M; Centre for Applied Health Economics, Griffith University, Nathan, QLD, 4111, Australia.
Pokaż więcej
Źródło :
Clinical drug investigation [Clin Drug Investig] 2020 Dec; Vol. 40 (12), pp. 1167-1176. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*economics
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Phenylurea Compounds/*economics
Quinolines/*economics
Sorafenib/*economics
Antineoplastic Agents/therapeutic use ; Australia ; Cost-Benefit Analysis ; Female ; Humans ; Male ; Phenylurea Compounds/therapeutic use ; Quality-Adjusted Life Years ; Quinolines/therapeutic use ; Sorafenib/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies